These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25956795)

  • 1. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
    Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
    Lancet Oncol; 2015 Jun; 16(6):695-703. PubMed ID: 25956795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib: a new drug for pancreatic neuroendocrine tumours.
    Kwekkeboom DJ
    Lancet Oncol; 2015 Jun; 16(6):606-7. PubMed ID: 25956796
    [No Abstract]   [Full Text] [Related]  

  • 3. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
    Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours.
    Ahn HK; Choi JY; Kim KM; Kim H; Choi SH; Park SH; Park JO; Lim HY; Kang WK; Lee J; Park YS
    Br J Cancer; 2013 Sep; 109(6):1414-9. PubMed ID: 23989950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
    Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA
    Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
    Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
    Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
    Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
    Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
    Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
    Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
    Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
    Reidy-Lagunes DL; Vakiani E; Segal MF; Hollywood EM; Tang LH; Solit DB; Pietanza MC; Capanu M; Saltz LB
    Cancer; 2012 Oct; 118(19):4795-800. PubMed ID: 22437754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
    Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
    Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
    Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
    Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
    Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
    Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.